212 related articles for article (PubMed ID: 36139434)
1. Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors.
Codenotti S; Zizioli D; Mignani L; Rezzola S; Tabellini G; Parolini S; Giacomini A; Asperti M; Poli M; Mandracchia D; Vezzoli M; Bernardi S; Russo D; Mitola S; Monti E; Triggiani L; Tomasini D; Gastaldello S; Cassandri M; Rota R; Marampon F; Fanzani A
Cells; 2022 Sep; 11(18):. PubMed ID: 36139434
[TBL] [Abstract][Full Text] [Related]
2. Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation.
Zhu Y; Pereira RO; O'Neill BT; Riehle C; Ilkun O; Wende AR; Rawlings TA; Zhang YC; Zhang Q; Klip A; Shiojima I; Walsh K; Abel ED
Mol Endocrinol; 2013 Jan; 27(1):172-84. PubMed ID: 23204326
[TBL] [Abstract][Full Text] [Related]
3. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
4. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts.
Cao X; Kambe F; Moeller LC; Refetoff S; Seo H
Mol Endocrinol; 2005 Jan; 19(1):102-12. PubMed ID: 15388791
[TBL] [Abstract][Full Text] [Related]
5. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
6. Pravastatin induces rat aortic endothelial cell proliferation and migration via activation of PI3K/Akt/mTOR/p70 S6 kinase signaling.
Nakao T; Shiota M; Tatemoto Y; Izumi Y; Iwao H
J Pharmacol Sci; 2007 Dec; 105(4):334-41. PubMed ID: 18057776
[TBL] [Abstract][Full Text] [Related]
7. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
8. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.
Tremblay F; Gagnon A; Veilleux A; Sorisky A; Marette A
Endocrinology; 2005 Mar; 146(3):1328-37. PubMed ID: 15576463
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake.
Ginion A; Auquier J; Benton CR; Mouton C; Vanoverschelde JL; Hue L; Horman S; Beauloye C; Bertrand L
Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H469-77. PubMed ID: 21602475
[TBL] [Abstract][Full Text] [Related]
10. L-threonine regulates G1/S phase transition of mouse embryonic stem cells via PI3K/Akt, MAPKs, and mTORC pathways.
Ryu JM; Han HJ
J Biol Chem; 2011 Jul; 286(27):23667-78. PubMed ID: 21550972
[TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis.
Faghiri Z; Bazan NG
Exp Eye Res; 2010 Jun; 90(6):718-25. PubMed ID: 20230819
[TBL] [Abstract][Full Text] [Related]
12. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
Bishop JD; Nien WL; Dauphinee SM; Too CK
J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
[TBL] [Abstract][Full Text] [Related]
13. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Renshaw J; Taylor KR; Bishop R; Valenti M; De Haven Brandon A; Gowan S; Eccles SA; Ruddle RR; Johnson LD; Raynaud FI; Selfe JL; Thway K; Pietsch T; Pearson AD; Shipley J
Clin Cancer Res; 2013 Nov; 19(21):5940-51. PubMed ID: 23918606
[TBL] [Abstract][Full Text] [Related]
14. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
15. Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines.
Kent MS; Collins CJ; Ye F
Am J Vet Res; 2009 Feb; 70(2):263-9. PubMed ID: 19231960
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells.
Minhajuddin M; Bijli KM; Fazal F; Sassano A; Nakayama KI; Hay N; Platanias LC; Rahman A
J Biol Chem; 2009 Feb; 284(7):4052-61. PubMed ID: 19074768
[TBL] [Abstract][Full Text] [Related]
17. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
18. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
Li YJ; Wang Y; Wang YY
J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
